Penwest Halts Beta Blocker Development Following "Not Approvable" Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm will halt development efforts for PW2101 due to FDA's concerns outlined in a "not approvable" letter and because of the limited commercial window for the product.
You may also be interested in...
Tarceva Pancreatic Cancer Indication Turned Down In The EU
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
Teva To Investigate High-Dose Copaxone
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.
J&J’s Velcade Is Not Cost-Effective For Multiple Myeloma, U.K.’s NICE Suggests
A National Institute for Health & Clinical Excellence analysis finds cost per quality-adjusted life year gained as high as $83,000.